ECM Therapeutics

ECM Therapeutics is a regenerative medicine company that develops and manufactures therapeutic products derived from extracellular matrix (ECM). The company was founded in 2018 and is based in Warrendale, Pennsylvania. Their patented ECM hydrogel technology aims to restore naturally occurring functional tissue following injury by utilizing the body's own template.

The company's technology utilizes naturally occurring extracellular matrix-based signaling molecules to treat unmet medical needs. Dr. Stephen Badylak, who holds over 60 U.S. patents and 300 worldwide, leads the scientific efforts. The platform provides cues for cell attachment, migration, proliferation, and 3-D spatial organization.

The company launched in November 2025 with a submission of a 510(k) application for ECM hydrogel for wound management. They also initiated an IDE clinical study in December 2025 to evaluate injectable ECM hydrogel for anorectal fistula repair. These recent developments show their active pipeline in regenerative medicine.

The company's timeline includes FDA approval of the first ECM-based bioscaffold in 1999 and the discovery of Matrix-Bound Nanovesicles in 2016. They have generated over 75 publications on ECM-based therapies since 2008. This history demonstrates their long-term commitment to ECM research.

Reviewers consistently praise the company's customer service for being responsive, helpful, and knowledgeable. Many users also highlight the user-friendly nature of their website and the seamless ordering process. The products are frequently described as high-quality and effective for improving health.

Some reviewers mention that the products have made a significant difference in their well-being and health. Others describe the experience as life-changing and highly recommend the company to others. The positive feedback focuses on product effectiveness and customer support quality.

The company's approach is described as science-driven, biologically intelligent, and patient-focused. They aim to push boundaries in regenerative medicine while prioritizing meaningful clinical outcomes. Their methodology is rooted in rigorous research and clinical evidence.

The company's products are designed to work with natural healing processes to restore function following injury and disease. They focus on harnessing the natural signaling network within tissues to achieve this goal. This biological intelligence is a core part of their therapeutic strategy.

The company's platform includes injectable ECM hydrogel and Matrix-Bound Nanovesicles (MBV) therapies. These products are intended for expanded, less invasive applications in multiple disease areas. The technology allows for targeted regeneration where it matters most.

The company's website states that they develop and manufacture diagnostic and therapeutic products derived from ECM. They also provide cues for cell attachment, migration, proliferation, and 3-D spatial organization. This comprehensive offering supports their regenerative medicine goals.

The company's website mentions that they are guided by decades of scientific research and clinical expertise. Dr. Badylak has served on the Scientific Advisory Board for several major medical device companies. This leadership provides credibility to their scientific claims.

The company's timeline shows a progression from early bioscaffold development to current clinical studies. They have built a foundation of scientific and clinical experience over time. This experience informs their current product development and clinical trial strategies.

The official website of ECM Therapeutics is ecmtherapeutics.com.

On Trustburn, ECM Therapeutics has a rating of 4 out of 5 based on 9 reviews.